Insmed Incorporated (INSM) Stock: Price, Forecast & Analyst Target
Insmed Incorporated (INSM) — MoonshotScore 31/100 (Weak band), calculated Nov 18, 2026. Price $119.80 (-1.69%), as of the Nov 18, 2026 trading session; market cap $26.3B.
Educational signal · not a buy or sell recommendation · How to read this
Insmed Incorporated · INSM · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-12: Insmed is a commercial rare-lung-disease biopharma built around ARIKAYCE while expanding through BRINSUPRI and TPIP. What matters is whether rapidly rising commercial revenue can outrun launch and clinical investment before liquidity erodes.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · Insmed (INSM)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Durable growth, but a strained balance sheet and a full valuation. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Average; Financial Safety: Strained; Valuation: Full; Growth Durability: Growing; Momentum: Rising.
- quarterly revenue $142M (Q3 FY2025, quarter ended Sep 2025)
- EPS beat 0 of the last 4 reports
- Altman Z 7.58 · Piotroski F 4
Holding back: balance-sheet strain
Helping: durable growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 30 | Weak | |
| 30 | Weak | |
| 30 | Weak | |
| 30 | Weak | |
| 31 | Weak | |
| 31 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $119.80 | |
| Change on the day | -1.69% | |
| 52-week range | $90.39–$212.75 | |
| Market capitalisation | $26.3B | — |
| Price / earnings (trailing) | 244.75 | |
| Shares traded on the day | 1.94M | |
| Beta (volatility vs the S&P 500) | 0.81 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Insmed (INSM): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
One of these lenses reads this company more favourably than the MoonshotScore does: Dalio-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Insmed (INSM), and what does it report?
Short answer · as of
Insmed is not a development-only biotechnology company. It markets ARIKAYCE as part of an antibacterial regimen for adults with MAC lung disease, while BRINSUPRI and the inhaled TPIP program broaden its exposure to bronchiectasis and other rare lung disorders.
Research dated 2026-09-12.
Revenue is reported within an aggregate segment rather than as separate product businesses. The headline income statement therefore measures the combined commercial operation, while research spending captures an unusually active pipeline alongside marketed therapies.
What do the latest results show for Insmed (INSM)?
Short answer · as of
The most recent reported quarter, Q3 FY2025, carried revenue of $142M.
Research dated 2026-09-12.
Revenue accelerated sharply and reached the high point of the reported quarterly series. Gross profit rose with it, the operating loss almost disappeared, and the net loss contracted dramatically; reported revenue and earnings also surpassed market estimates. Operating cash use improved but remained negative, so accounting progress has not yet become cash generation.
Management links the commercial outlook to BRINSUPRI patient starts and expects net realization from the product to remain within its updated range. At the same time, it plans heavier spending on the BRINSUPRI launch, TPIP clinical programs, consumer promotion, and commercial infrastructure in Japan, creating a direct test of whether adoption can scale faster than the supporting cost base.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2025 | $142M | -$370M | -$1.75 (diluted) |
| Q4 FY2025 | $264M | -$328M | -$1.54 (diluted) |
| Q1 FY2026 | $306M | -$164M | -$0.76 (diluted) |
| Q2 FY2026 | $425M | -$13M | -$0.06 (diluted) |
What are the financial strengths and risks for Insmed (INSM)?
Short answer
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-12.
Cash and short-term investments exceed total debt, and the liquidity ratios indicate substantial near-term coverage. The balance carries no separately classified long-term investments, so the readily available pool is the relevant funding base.
That cushion is being consumed. Operating cash flow has remained negative throughout the displayed series, cash finished below its opening level across the measured window, and the internally calculated runway is finite. Management believes current resources can carry the business through cash-flow positivity without another capital raise, but that claim depends on the recent earnings improvement persisting while launch and research spending expand.
Valuation adds execution pressure: net cash is small relative to market value, while sales and book multiples are elevated despite negative trailing profitability. The wide range of longer-horizon revenue estimates shows how sensitive the narrative remains to commercial uptake and pipeline delivery.
Data-derived red flags
- Negative return on equity (-72.5%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
- Rich valuation — a P/E of 244.75 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.
What should you watch next at Insmed (INSM)?
Short answer · as of
Current published price targets run low $154.00 · high $235.00 · consensus $191.06 · median $193.50 against a quoted price of $119.80 (as of Nov 18, 2026).
Research dated 2026-09-12.
BRINSUPRI patient starts, realized revenue after concessions, and sequential revenue growth are the most direct commercial checks. The scheduled earnings release also provides a clear comparison against market expectations after recent results exceeded revenue and earnings estimates.
Cash use deserves equal attention. Watch whether operating cash outflow continues to narrow even as Insmed funds branded promotion, Japanese commercial infrastructure, and TPIP development; renewed deterioration would weaken management’s assertion that existing resources can bridge the company to cash generation.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
- The newest quarter held here (Q3 FY2025) was filed Oct 30, 2025 — 12 months ago.
Checked against the records this page reads, on the dates shown above.
How does Insmed compare with its peers?
Short answer
Insmed's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
Insmed sits between development-stage biotechnology and mature specialty pharmaceuticals. ARIKAYCE already gives it a commercial rare-lung-disease franchise, while BRINSUPRI commercialization and TPIP development preserve the clinical and launch risk normally associated with a pipeline company.
Its aggregate segment presentation also differs from businesses that disclose mature product franchises separately. Investors must judge the commercial transition through consolidated revenue, margins, spending, and cash use rather than clean product-level profit lines.
| Company | Price | Market value | Score |
|---|---|---|---|
| $68.29 Nov 18, 2026 | $16.7B | 98 5-pillar Nov 18, 2026 | |
| $577.34 Nov 18, 2026 | $24.6B | 97 5-pillar Nov 18, 2026 | |
| $270.33 Nov 18, 2026 | $17.7B | 96 5-pillar Nov 18, 2026 | |
| $941.25 Nov 18, 2026 | $59.2B | 96 5-pillar Nov 18, 2026 | |
| $162.86 Nov 18, 2026 | $16.5B | 95 5-pillar Nov 18, 2026 | |
| $72.75 Nov 18, 2026 | $11.4B | 92 5-pillar Nov 18, 2026 | |
| $117.80 Nov 18, 2026 | $24.0B | 91 5-pillar Nov 18, 2026 | |
| $278.35 Nov 18, 2026 | $64.3B | 88 5-pillar Nov 18, 2026 | |
| $177.33 Nov 18, 2026 | $50.0B | 83 5-pillar Nov 18, 2026 | |
| $385.78 Nov 18, 2026 | $46.3B | 79 5-pillar Nov 18, 2026 | |
| $9.08 Nov 18, 2026 | $39.8B | 75 5-pillar Nov 18, 2026 | |
| $21.27 Nov 18, 2026 | $68.0B | 73 5-pillar Nov 18, 2026 | |
| Insmed (INSM) — this page | $119.80 | $26.3B | 31 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $154.00 – $235.00
- Consensus target
- $191.06
- Median target
- $193.50
Consensus record · Captured .
Measured against a quoted price of $119.80 (as of Nov 18, 2026).
Insider activity
Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Oct 19, 2026
- Transactions
- 55
- Identified insiders
- 10
- Purchases
- 0
- Sales
- 25
- Other transactions
- 30
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held INSM in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Duquesne Family Office | Stanley Druckenmiller | Q3 2026 | 2.79% | $124.72M | Trimmed −23.3% shares |
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.19% | $44.07M | Trimmed −15.2% shares |
| Duquesne Family Office | Stanley Druckenmiller | Q3 2026 | 1.40% | $62.78M | Call options · Trimmed −59.3% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Insmed (INSM)?
What Investors Ask About Insmed (INSM) — Healthcare
Research dated 2026-09-12; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
How does ARIKAYCE make Insmed different from a development-stage biotech?
ARIKAYCE gives Insmed an existing commercial business serving adults with MAC lung disease, so reported revenue reflects marketed therapy rather than only licensing or research activity. Pipeline execution still matters because BRINSUPRI and TPIP carry much of the expansion opportunity.
Why are BRINSUPRI patient starts important for Insmed?
Patient starts are management’s stated bridge between launch activity and higher revenue. Their value depends on sustained treatment demand and the net revenue retained after concessions.
What does TPIP spending mean for Insmed’s cash profile?
TPIP adds clinical investment while the company is still using cash in operations. Progress can expand Insmed’s rare-lung pipeline, but spending on those programs competes with BRINSUPRI commercialization for the same liquidity pool.
Can Insmed fund BRINSUPRI commercialization without new capital?
Management believes existing resources can fund the business through cash-flow positivity without another raise, and liquid assets currently exceed debt. Continued negative operating cash flow and planned commercial investment make that conclusion dependent on revenue scaling and cash use improving together.
What is the INSM stock price today?
The last price recorded for Insmed Incorporated (INSM), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the INSM price target?
The analyst consensus price target for Insmed Incorporated (INSM), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 27 figures on this page — 1 from SEC filings and earnings calls, 22 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com